Quality indicators (QI.8–24), part 2: specific aspects (drug safety, care for elderly and diseases-related)
| No. of QI/category | Variable | N (%) |
| Drug safety | ||
| QI.8 | From subgroup: ≥1 prescription of anxiolytics, sedatives or hypnotics | |
| Number of prescriptions | ||
| 1 | 49 728 (56.4) | |
| 2 | 15 490 (17.6) | |
| ≥3 | 23 015 (26.1) | |
| QI.9 | From subgroup: ≥1 prescription of non-steroidal anti-inflammatory drugs | |
| Number of prescriptions | ||
| 1 | 108 320 (55.3) | |
| 2 | 44 700 (22.8) | |
| ≥3 | 42 701 (21.8) | |
| Care for elderly | ||
| QI.10 | From subgroup: ≥65 years and ≥1 medication prescription | |
| Polymedication | 78 156 (53.3) | |
| QI.11 | From subgroup: ≥65 years and ≥1 medication prescription | |
| Potentially inappropriate medication | 48 600 (33.1) | |
| QI.12 | From subgroup: ≥65 years | |
| Influenza vaccination | 30 208 (18.2) | |
| QI.13 | From subgroup: ≥65 years and ≥1 chronic condition | |
| Hospitalised for fracture near the pelvic joint | 399 (0.3) | |
| Disease-specific | ||
| QI.14 | From subgroup: patients with respiratory disease | |
| Long-term therapy of corticosteroids | 1106 (2.2) | |
| QI.15 | From subgroup: patients with respiratory disease | |
| Disease-specific hospitalisation | 709 (1.4) | |
| QI.16 | From subgroup: patients with diabetes mellitus | |
| HbA1c control | 32 770 (89.3) | |
| QI.17 | From subgroup: patients with diabetes mellitus | |
| Ophthalmological control | 18 493 (50.4) | |
| QI.18 | From subgroup: patients with diabetes mellitus | |
| Hospitalisation | 7303 (19.9) | |
| QI.19 | From subgroup: patients with diabetes mellitus | |
| Control of lipid values | 23 535 (64.1) | |
| QI.20 | From subgroup: patients with diabetes mellitus | |
| Control of kidney values | 17 345 (47.2) | |
| QI.21 | From subgroup: patients with myocardial infarction | |
| Receiving ASS within 12 months after event | 1210 (94.2) | |
| QI.22 | From subgroup: patients with myocardial infarction | |
| Receiving statins within 12 months after event | 1127 (87.8) | |
| QI.23 | From subgroup: patients with stroke or TIA | |
| Receiving ASS within 12 months after event | 391 (75.5) | |
| QI.24 | From subgroup: patients with stroke or TIA | |
| Receiving statins within 12 months after event | 386 (74.5) | |
ASS, aspirin; HbA1c, glycated haemoglobin; QI, quality indicator; TIA, transient ischaemic attack.